News | December 2, 2024
Devyser achieves Class D IVDR approval for its RHD product
Find out more
All articles
Devyser at 20: Celebrating two decades of innovation in genetic diagnostics
.png)
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoring
Devyser Compact achieves Class III approval in China
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation
Streamlining familial hypercholesterolemia testing: How Sahlgrenska University Hospital laboratory optimized workflow with Devyser FH
.png)
New insights into thalassemia: Latest studies using Devyser Thalassemia for NGS testing
.png)
Devyser Diagnostics AB publishes quarterly report for the period April to June 2024
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with...
.png)
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK
.png)
Meeting Modern Demands: Overcoming Thalassemia Testing Challenges with NGS
.png)
One-size-fits-all: Addressing hemoglobinopathy using NGS
.png)